Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed Launches National Search For New CEO As Ubl Plans Departure

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed CEO Steve Ubl is leaving the device trade association to take the helm of the Pharmaceutical Research and Manufacturers of America. Ubl has led AdvaMed for 10 years, raising the profile of the device industry among policymakers, fighting perception battles and, of course, opposing the device tax.

Advertisement

Related Content

Next AdvaMed Chief Is BIO Exec Scott Whitaker
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Device Industry Amps Up Efforts To Repeal Device Tax In Lame Duck Session
Device Industry Continues Push To Influence Health Care Reform Dialogue
It’s The Economy, Stupid: “Value” Campaign To Stress System-Wide Savings
AdvaMed Escalates Opposition To Inpatient Proposal With Ad Campaign
Device Industry Aims To Prevent Image Problems That Have Plagued Pharma
AdvaMed President Ubl Brings Detailed Policy Approach To Industry Agenda

Topics

Advertisement
UsernamePublicRestriction

Register

MT034225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel